A novel PET technique combining a diagnostic radionuclide with a therapeutic agent can now map the potential results of therapy for advanced renal cell carcinoma, according to a study published Dec. 4 in the Journal of Nuclear Medicine. 

The genomics market is expected to grow at an annual compound growth rate of 7.28 percent from 2013 to 2018, according to a recent market report from market research firms Infiniti Research Limited and TechNavio. 

The diagnostic imaging markets in Brazil, Russia, India and China—known as the BRIC markets, are expected to grow at a compound annual growth rate of 10.5 percent, reaching $7.6 billion within the next four years.

PET has dominated the amyloid imaging ring for several years now, but a preclinical study is showing some signs that SPECT could give PET a run for its money eventually, especially in translational research, according to a study published Dec. 4 in the Journal of Nuclear Medicine.

A protein that suppresses immune response could tell researchers how patients taking a novel cancer immunotherapy will fare, Yale officials announced Nov. 26. The discovery could predict immune response in the treatment of a wide variety of cancers.

Cambridge, Mass., based biomedical company Biogen Idec announced encouraging results of a phase II drug targeting amyloid in Alzheimer’s patients at a Deutsche Bank conference in Boston today.

Early detection of blood cancers may be getting a big push with the discovery of a pre-cancerous state of genetic mutation in lymphomas, leukemia, myelodysplastic syndrome and other blood diseases. The biomarker is easily detectable in peripheral blood samples, according to two major studies published online Nov. 26 in the New England Journal of Medicine.

Philips Healthcare has won the title of the 2014 North America Award for Technology Innovation Leadership from the market research firm Frost & Sullivan based on the integrated technology of the Vereos digital PET/CT system, Frost & Sullivan officials announced Nov. 26.